Our study confirms the possible influence of hypomethylation and upregulated expression of CRY1 in prognostically poor IGHV unmutated CLL and further emphasises its role as potential biomarker for relative risk of treatment initiation and TTFT in early stage CLL. This evidence concerns the gene CRY1 and B-cell chronic lymphocytic leukemia.